BioSpace News Archive

Elixir Medical announced it will present primary endpoint and 6-month data from its DESyne BDS Plus Randomized Clinical Trial (RCT), a prospective, multicenter, single-blind study, as part of The Innovation Program at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

Clene Inc. (Nasdaq: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, has been awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH), to support an Expanded Access Protocol (EAP) for the Company’s investigational drug, CNM-Au8®, in amyotrophic lateral sclerosis (ALS).

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR trial investigating EYLEA® HD (aflibercept) Injection 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® (aflibercept) Injection, in patients with wet age-related macular degeneration (wAMD).

Realizing a vision to deliver the best care to patients close to where they live in northern Ohio, GE HealthCare and University Hospitals announced a 10-year strategic collaboration to bring GE HealthCare technologies to UH across its radiology practice and UH Harrington Heart & Vascular Institute, providing contemporary equipment and digital solutions to improve processes for the benefit of patients and clinicians.

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the publication of the development and characterization of a highly purified population of human stem cell-derived, pallial-specific MGE inhibitory interneurons for the potential treatment of focal epilepsy.

Join the Association for Diagnostics & Laboratory Medicine and leading experts in laboratory medicine and pediatric health for a discussion about what needs to be done to improve pediatric reference intervals and why this is critical to ensuring that children get effective care.

Biological Dynamics, Inc. will present a “lightning talk” as part of the “Understanding Pre-cancers to Enable Early Detection” track at the Early Detection of Cancer Conference, Oct. 10-12, 2023, in London.

Küleon LLC, a private biotechnology company that has built the industry’s largest library of serotonergic drugs exhibiting G protein-biased signaling (i.e., “functionally selective” ligands), today announced the development of what is believed to be the world’s first “trifunctional” serotonergic small molecule that is a full 5-HT2C receptor agonist and full antagonist of the 5-HT2A and 5-HT2B receptors.

Elligo Health Research®, the largest healthcare-enabling research organization, announced it is expanding its Study Marketplace platform with Syneos Health, a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success.

Experic, a contract development and manufacturing organization (CDMO) and clinical supply services company serving the biopharmaceutical industry